ContraVir Pharmaceuticals Культура компании

Dr. Theresa Matkovits, Ph.D., has been Chief Operating Officer of ContraVir Pharmaceuticals, Inc. since December 2017. Dr. Matkovits served as an Executive Vice President and Head of Drug Development at ContraVir Pharmaceuticals, Inc., since July 18, 2017. Dr. Matkovits served as Senior Vice President of Drug Development at ContraVir Pharmaceuticals, Inc. since May 26, 2015 until July 18, 2017 and its Vice President of Product Development until June 22, 2016. She has over 20 years global drug development, commercialization and leadership experience. A seasoned and established leader in the Pharmaceutical and Biotech Sectors, Dr. Matkovits has led Global Drug Development Teams bringing to market a number of approved medicines to several global markets. Dr. Matkovits started her career at the Roche Institute of Molecular Biology and Organon where she held positions in clinical development in the Women's Health area. In 1997, Dr. Matkovits joined Novartis in Global Drug Development, taking on leadership roles in the clinical development for the marketed antipsychotic, Fanapt. Dr. Matkovits advanced her career in Novartis, taking on Global Drug Development leadership for the CNS Psychiatry Portfolio including Schizophrenia, Anxiety Disorders and Depression. She served as Global Program Leader for a number of early-phase, mid-phase and late-phase development compounds and in-line brands such as Clozaril. In 2010, Dr. Matkovits transitioned to the US commercial organization in Novartis where she lead the Strategic Planning and Operations Group for the General Medicines Portfolio in Medical Affairs. Dr, Matkovits was responsible for the oversight and leadership of Continuing Medical Education, Resource and Strategic Planning, Organizational Development and Training, Compliance, Project Management, IT for the Field Medical Team and the establishment of a REMs Center of Excellence. Dr. Matkovits subsequently joined The Medicines Company in 2010 as Vice President, Innovation Leader, where she was recruited and lead the successful global development and registration of oritavancin, which is now approved and commercialized in the US and EU as ORBACTIV. In 2013, Dr. Matkovits joined NPS Pharmaceuticals as a consultant to the Chief Executive Officer to lead the integration of two commercial assets acquired from Takeda into NPS. Dr. Matkovits played a critical role in driving the expansion of NPS from a US-centric to a global development and commercial organization. In 2012, Dr. Matkovits joined NPS as Global Program Leader to lead the registration of Natpara for the US and EU Markets. Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of NJ.

Mr. John T. Cavan has been the Chief Financial Officer at ContraVir Pharmaceuticals, Inc. since April 1, 2016. Mr. Cavan has more than 20 years of financial management experience in both public and private companies. Prior to joining ContraVir as an Interim Chief Financial Officer, he served as a Consultant with The Pine Hill Group where he was instrumental in finishing several financial transactions, including initial public offerings, business combinations and strategic transactions. He served as the Chief Accounting Officer of Stemline Therapeutics, Inc., from March 2012 to August 2012. He served as the Chief Accounting Officer and Vice President of Aegerion Pharmaceuticals, Inc. from February 2009 to February 29, 2012. He served as Corporate Controller of Aegerion Pharmaceuticals from May 2006 to February 2009. Prior to Aegerion, he served as Controller of AlgoRx Pharmaceuticals from 2004 to 2006. He served in a variety of financial and operational positions through his prior work with large multinational public companies, which included Sony, American Express, International Specialty Products and Nestle. He serves on the Board of Directors of Vantage Health Systems. Mr. Cavan holds a BBA in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University.

John Cavan serves as the Chief Financial Officer of ContraVir Pharmaceuticals, Inc.. John started at ContraVir Pharmaceuticals, Inc. in Jan of 2016. John currently resides in the Greater New York City Area.

John Sullivan-Bolyai serves as the Chief Medical Officer of ContraVir Pharmaceuticals, Inc.. John started at ContraVir Pharmaceuticals, Inc. in Jan of 2015. John currently resides in the Greater Boston Area.